November/December 2010, Vol 3, No 6
There may be discordance between what pharmacists say influences their formulary decision choices, and what actually influences those choices, according to an exploratory study examining the importance of product and manufacturer attributes.
The method used to measure medication adherence impacts the results of that measurement, and therefore researchers should use various methods depending on the overall goals of the study, according to researchers from the Accredo Health Group and Medco Health Solutions.
A pilot program in which specialty pharmacists monitored hemoglobin levels in patients whose physicians had requested refills of erythropoiesisstimulating agents (ESAs) resulted in some dosing changes and significant drug costsavings for payers.
Preliminary research on incorporating a clinical pharmacist specialist into a team managing a patientcentered medical home (PCMH) shows an emerging body of evidence to support the integration of these specialists, and the potential for costsavings once these caregivers are added to the team.
A yearlong steptherapy program focusing on 10 therapeutic drug classes that also attempted to minimize member dissatisfaction with any changes among these drugs lowered the average gross cost per claim by nearly 13% while denying only 10.2% of prior authorization (PA) requests.
Employing mandatory 90day supply requirements for oral chemotherapy agents leads to drug waste and increased costs, and a shorterterm (30day) supply should be considered for these agents, according to a pharmacy claims database analysis.
Finding ways to care for chronically ill Americans is quickly becoming one of the singular most critical healthcare challenges of our nation. Nearly 1 of 2 Americans has diabetes, heart disease, or another chronic disease.1 Millions more are at risk, and this generation of youngsters may be the first in history to have poorer health at an earlier age and lower levels of longevity than their parents.2
The outlook for generics for the next 4 or 5 years continues to shine, judging from patent expiration dates for many of the topselling drugs. The generics “pipeline,” therefore, practically ensures that the past several years’ trend of increasing market share for generics will continue with a vengeance.
Page 1 of 2
Results 1 - 10 of 12
Results 1 - 10 of 12